- Release Date: 28/11/13 12:58
- Summary: GENERAL: PEB: PE signs Cxbladder agreement with 3rd national provider-US
- Price Sensitive: No
- Download Document 7.75KB
PEB 28/11/2013 10:58 GENERAL REL: 1058 HRS Pacific Edge Limited GENERAL: PEB: PE signs Cxbladder agreement with 3rd national provider-US 28 November 2013 Pacific Edge signs Cxbladder(TM) agreement with third national provider network in the US Pacific Edge has signed an agreement with Stratose, a large national provider network in the USA, to enable the provision of Cxbladder to patients through its large network of payers and providers. Stratose, one of the largest directly managed participating provider networks in the United States contracts with more than 850,000 direct and affiliate healthcare providers and offers a medical network solution for more than 8.6 million Americans through its client base consisting of insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans. The agreement is the third signed by Pacific Edge with national provider network organisations who contract with medical doctors, hospitals, and other health care providers who have covenanted with an insurer or a third-party administrator to provide health care to insured patients. The agreement with Stratose follows Pacific Edge's recent announcements of agreements with FedMed and ACPN providing 40 million and 14 million Americans respectively with access to Cxbladder.1 Pacific Edge Chief Executive Officer David Darling says agreements with national provider network organisations are a significant component in Pacific Edge's commercial roll-out of Cxbladder in the United States, the world's largest single healthcare market. "The endorsement of these agencies provides a clear commercial process linking providers and payers and signals to clinicians across the United States the availability of Cxbladder. The addition of Stratose along with FedMed and ACPN now provides network coverage to a significant pool of American people giving commercial access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test, all of which are particularly appealing to US healthcare professionals, patients, and insurers alike." Pacific Edge, through its wholly owned subsidiary Pacific Edge Diagnostics USA (PEDUSA) has already achieved the first commercial sales of Cxbladder in the US2 and is processing commercial samples, collected using its proprietary Urine Sampling System, at its custom built laboratory in Hershey, Pennsylvania. "Our sales and marketing teams are now focussed on the clinicians who are treating the largest number of bladder cancer patients to ensure they fully understand the benefits of Cxbladder," says Jackie Walker, Chief Executive Officer PEDUSA. "In addition, we are working with large commercial payers and the Centre for Medicare and Medicaid Services (CMS), which provides healthcare insurance to approximately 150 million people. Other large urology customers being targeted include the large Integrated Healthcare Systems, the Veterans Administration (VA), and Large Urology Group Practices (LUGS), who are the point of contact for many patients presenting with haematuria (blood in the urine) which is an early indicator of possible bladder cancer." More than one million Americans will undergo medical investigation this year for potential bladder cancer at an estimated cost of $US1 billion. Bladder cancer is one of the most expensive cancers to treat. The very high recurrence of this disease, requiring some patients to receive expensive monitoring for the rest of their lives, causes bladder cancer to have the highest total medical costs of any cancer from detection to death. In the US, the total medical cost approaches $US220,000 per patient. 1 http://www.pacificedge.co.nz/news-and-media/news/pacific-edge-agreement-with- national-providernetwork-fedmed-gives-40-million-americans-access-to-cxbladde r/;http://www.pacificedge.co.nz/news-and-media/news/pacific-edge-signs-agreem ent-with-americas-choice-provider-network-to-expand-access-to-cxbladder-in-th e-us/ 2 http://www.pacificedgedx.com/news-and-media/news/first-commercial-sales-achie ved-for-pacificedges-cxbladder-in-the-usa/ For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 ABOUT PACIFIC EDGE Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. Products in development and in clinical trials are accurate and simple to use genomic and proteomic tools for the earlier detection, improved characterisation and better management of gastric, bladder, colorectal cancers and melanoma. The company has recently completed and released its first product for the detection of bladder cancer, Cxbladder, and is actively marketing the product to urologists in New Zealand, Australia and soon to be Spain and the US. www.pacificedge.co.nz ABOUT PACIFIC EDGE DIAGNOSTICS Pacific Edge takes its exciting cancer detection tests to market through its wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge Diagnostics USA Ltd, and selected commercial partners in Australia and Spain, Healthscope and Oryzon respectively. www.pacificedgedx.com ABOUT Cxbladder Cxbladder is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder cancer from a small volume of urine. It provides general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy. The recently published, Journal of Urology in September 2012, multi-centre international clinical study recruited 485 patients from Australia and New Zealand. Results show that Cxbladder out-performed all of the benchmark technologies in the clinical trial and detected nearly all of the tumours of concern to a urologist; At a performance of 82% sensitivity and 85% specificity the test sees 100% of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper urinary tract cancers as well as greater than 95% of high grade tumours. www.cxbladder.com ABOUT BLADDER CANCER Globally, bladder cancer has the 9th highest incidence and the 4th highest incidence for men. One of the early symptoms of bladder cancer is the presence of blood in the urine, haematuria. People with haematuria often present to their general practitioner before being referred on to a urologist. There are a number of 'at risk' occupations that have shown a much higher incidence of bladder cancer. Fire fighters and fire control officers have shown in a US study to have a twice the incidence of bladder cancer over non fire fighters. Smoking is a significant contributing factor (over 50% in males and 33% in females, and approximately one of every two new incidences of bladder cancer is linked to smoking). Exposure to certain industrial chemicals or carcinogens increases risks for some occupations e.g. hairdressers, painters, printers, fire fighters and metal workers and chemical engineers. Incidence increases with age so the older you are, the greater the potential for bladder cancer. Bladder cancer has a very high recurrence rate of approximately 50%-70% with up to 30% of these recurring as later stage tumours. This is a higher recurrence than for skin cancer! However, bladder cancers are highly treatable, especially if detected in the early stages. If diagnosed early there is a much higher probability of survival for early stage tumours relative to later stage tumours. This makes timely and regular surveillance and monitoring of this cancer a key element of the clinical process and of the individual's annual healthcare plan. End CA:00244427 For:PEB Type:GENERAL Time:2013-11-28 10:58:14
- Forums
- NZX - By Stock
- PEB
- Ann: GENERAL: PEB: PE signs Cxbladder agreement w
Ann: GENERAL: PEB: PE signs Cxbladder agreement w
Featured News
Add PEB (NZSX) to my watchlist
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online